The acquisition provides immediate revenue and strategic expansion into nephrology and retinal disease, with strong growth visibility. Traders should monitor SYFOVRE® sales trajectory and upcoming FDA submission for prefilled syringe in H1 2026, which could accelerate adoption. The CVR structure aligns incentives and limits near-term dilution, while Biogen’s plan to de-lever by 2027 supports financial stability.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 31 $182.52entry
- T+1 · 8mo ago +0.31%α −0.44% · $183.08
- T+5 · 7mo ago −1.43%α −5.38% · $179.90
- T+20 · 7mo ago +4.31%α −5.11% · $190.39
- T+60 · 5mo ago +10.65%α −2.26% · $201.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Biogen announced the acquisition of Apellis Pharmaceuticals for $41 per share in cash, totaling $5.6 billion in upfront equity consideration, plus a contingent value right (CVR) tied to SYFOVRE® sales milestones. The deal adds two FDA-approved complement-targeting therapies, EMPAVELI® and SYFOVRE®, with combined 2025 revenue of $689 million and expected mid-to-high teens growth through 2028, enhancing Biogen’s immunology and nephrology portfolio.
Key Financial Metrics
Key Facts
- Biogen to acquire Apellis for $41 per share in cash, representing an 86% premium to Apellis’s 90-day volume-weighted average price.
- Total upfront equity value is $5.6 billion; additional CVR of up to $4 per share based on SYFOVRE® global net sales milestones ($1.5B and $2B thresholds between 2027–2030, or $2B in 2031).
- EMPAVELI® and SYFOVRE® generated combined net revenue of $689 million in 2025, expected to grow at mid-to-high teens rate at least through 2028.
- Transaction expected to be accretive to Biogen’s non-GAAP EPS starting in 2027 and boost its non-GAAP EPS CAGR through the end of the decade.
- Deal expected to close in Q2 2026, financed via cash and borrowings; Biogen expects to de-lever fully by end of 2027.
Financial Impact
$5.6 billion upfront cash outlay with potential $4 per share CVR payout; adds $689 million in annual revenue with strong growth trajectory
Risk Factors
- Failure to achieve SYFOVRE® sales milestones could result in no CVR payout, reducing deal upside.
- Integration risk and potential disruption to Apellis’s commercial momentum in key rare disease markets.
- Regulatory or antitrust delays could push closing beyond Q2 2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265288 |
Track record
34 reports on BIIB
9 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers